People with the lung ailment chronic
obstructive pulmonary disease are more likely to get pneumonia if they use
inhaled corticosteroid drugs and doctors should be more cautious in prescribing
them, researchers said.
People with smoking-related chronic obstructive pulmonary disease, or
COPD, who took the drugs for symptoms such as cough, wheezing, shortness of
breath and exhaustion from light exercise were 34 percent more likely to develop
pneumonia than those who did not, according to a study published on Tuesday.
COPD includes emphysema and chronic bronchitis.
Writing in the Journal of the American Medical Association, Dr. Brad
Drummond of Johns Hopkins University in Baltimore and colleagues pooled the
results of 11 previously published studies involving more than 14,000 COPD
patients.
The patients used drugs including AstraZeneca Plc's Pulmicort, or
budesonide; Abbott Laboratories' Azmacort, or triamcinolone; GlaxoSmithKline's
Flovent, or fluticasone, and Advair, which combines the corticosteroid Flovent
with a long-acting beta-agonist.
"For physicians, the message from our study is that they should evaluate
a patient's individual characteristics before prescribing inhaled steroids,"
Drummond said in a telephone interview.
"If a patient is burdened by significant symptoms such as shortness of
breath, cough or exercise intolerance, previous studies have shown that inhaled
steroids are quite effective. However, if a patient has relatively few symptoms
or if a lung infection would be potentially life threatening, then inhaled
steroids may be of more harm than benefit," he said.
The COPD patients at especially high risk for pneumonia included those
with the poorest lung function -- less than 40 percent of what it should be --
as well as those using the highest dose of inhaled steroids and those who used
the drugs combined with other inhaled medications.
"However, this should not compel patients to stop taking their inhaled
steroids," Drummond added.
But COPD patients should speak with their doctor about the benefits and
risks of inhaled steroids, Drummond said.
"Inhaled corticosteroids are not of equal benefit to all and what we are
seeing is that the treatment may be more harmful and pose a greater risk of harm
to some," said Dr. Eddy Fan of Johns Hopkins, another of the researchers.
The researchers said the reason the drugs raise the risk of pneumonia is
unclear but they may suppress the immune system.
COPD, typically caused by cigarette smoking, refers to a group of
incurable and irreversible chronic lung ailments in which the airways in the
lungs are obstructed. It is a leading cause of death globally and the
fourth-leading cause of death in the United States.
The study also found that COPD patients who take these drugs are no more
or less likely to die than those who do not. They also have no greater risk of
bone fractures, which had been a concern because certain oral steroids are known
to increase of osteoporosis and fracture risk.
(Editing by Julie Steenhuysen and Bill Trott) Keywords: LUNG STEROIDS
(will.dunham@reuters.com; +1-202-898-8300, Reuters Messaging:
will.dunham.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2008. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including
by framing or similar means, is expressly prohibited without the prior written
Copyright 2008 AFX News Limited. All Rights Reserved.